Avoid Benzodiazepines Including Lorazepam in Geriatric Anxiety Management
For a geriatric patient with a history of lorazepam (Ativan) use, the safest anxiety medication options are SSRIs (particularly sertraline or escitalopram as first-line), or buspirone for relatively healthy older adults, with benzodiazepines like lorazepam strongly discouraged due to excessive risk of falls, cognitive impairment, delirium, and mortality. 1, 2, 3
Why Lorazepam Should Be Discontinued
The 2019 AGS Beers Criteria explicitly recommends avoiding all benzodiazepines in older adults due to increased sensitivity and substantial risks including 1:
- Falls and fractures (highest concern for morbidity)
- Cognitive impairment and delirium
- Physical dependence and withdrawal complications
- Motor vehicle crashes
- Increased mortality risk
The most recent 2025 systematic review provides even stronger evidence: benzodiazepines, particularly midazolam but including lorazepam, showed increased adverse events with escalating doses and posed excessive risk without clinical efficacy gains in older adults 2. Adverse drug events occurred in 16.8% of older adults receiving anxiolytic medications, with benzodiazepines carrying disproportionate risk 2.
The FDA label for Ativan confirms these concerns, noting that elderly patients experience more profound and prolonged sedation, with effects lasting longer than 6-8 hours and requiring 24-48 hours before resuming normal activities 4.
Recommended First-Line Treatment Algorithm
Step 1: SSRIs (Preferred Initial Choice)
- Sertraline or escitalopram are specifically recommended as first-line agents 3
- These have favorable pharmacokinetic profiles with less drug interaction potential
- Effective for both anxiety and commonly comorbid depression 5, 6
Dosing strategy for older adults:
- Start at low doses to avoid initial anxiety exacerbation
- Gradually titrate to therapeutic range
- Provide frequent follow-up during first weeks 7
Step 2: Alternative First-Line Options
- Buspirone (18 mg/day mean dose): Well-tolerated in elderly patients with multiple comorbidities, proven effective in controlled trials 8, 3
- Consider if avoiding sexual side effects is priority in relatively healthy older adults
Step 3: Second-Line SSRI or SNRI
If inadequate response to first SSRI:
- Try different SSRI, or
- Venlafaxine or duloxetine (SNRIs) 3
Step 4: Third-Line Options
- Pregabalin/gabapentin
- Lavender oil
- Agomelatine 3
Step 5: Quetiapine (Last Resort)
Only after failure of above options, with careful monitoring 3
Critical Pitfalls to Avoid
Do not use:
- Tricyclic antidepressants (TCAs): Suboptimal safety profile in elderly 5
- MAO inhibitors: Excessive side effects 5
- Benzodiazepines: Black box warning territory given fall/fracture risk 1
- Hydroxyzine: Anticholinergic properties contraindicated 2
Common mistake: Continuing benzodiazepines started in younger adulthood. Many patients with GAD were appropriately started on benzodiazepines when younger, but regular reassessment is mandatory to determine if harms now exceed benefits, warranting switch to recommended agents 3, 9.
If Patient Currently Takes Lorazepam
Tapering is essential - abrupt discontinuation can precipitate life-threatening withdrawal reactions 4. The FDA label warns that withdrawal symptoms can last weeks to over 12 months in some cases 4.
Transition strategy:
- Initiate SSRI (sertraline or escitalopram) at low dose
- Begin slow lorazepam taper only after SSRI reaches therapeutic effect (typically 4-6 weeks)
- Consider short-term adjunctive lorazepam during SSRI initiation if severe anxiety, but plan definitive discontinuation 7
Special Considerations
Comorbid depression: Present in majority of geriatric anxiety cases - SSRIs address both conditions simultaneously, making them superior to benzodiazepines 6, 9
Multiple medical comorbidities: SSRIs and buspirone proven safe in elderly patients receiving multiple concomitant medications for chronic conditions 8
Oral administration preferred: When any anxiolytic is necessary, oral formulations have better safety profiles than IV/IM routes 2
The evidence unequivocally supports transitioning away from lorazepam to SSRI-based therapy, with buspirone as an alternative first-line option for appropriate candidates.